Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CEMI

Chembio Diagnostics (CEMI) Stock Price, News & Analysis

Chembio Diagnostics logo

About Chembio Diagnostics Stock (NASDAQ:CEMI)

Advanced Chart

Key Stats

Today's Range
$0.45
$0.46
50-Day Range
$0.33
$0.46
52-Week Range
$0.19
$1.24
Volume
351,642 shs
Average Volume
661,416 shs
Market Capitalization
$16.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Stock News Headlines

Quest Diagnostics Inc DGX
The Shadow President?
President Trump has already launched a "shock and awe" flurry of new Executive Orders... He's withdrawn from the World Health Organization... exited the Paris climate accord... and begun dismantling many Federal programs... But there's ONE executive order that could go down in history as the most important of all.
See More Headlines

CEMI Stock Analysis - Frequently Asked Questions

Chembio Diagnostics, Inc. (NASDAQ:CEMI) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.05. The firm had revenue of $12.06 million for the quarter. Chembio Diagnostics had a negative net margin of 47.03% and a negative trailing twelve-month return on equity of 113.57%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), NovoCure (NVCR), BlackRock Capital Investment (BKCC), Viper Energy (VNOM) and Summit Midstream Partners (SMLP).

Company Calendar

Last Earnings
11/04/2021
Today
2/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CEMI
Employees
337
Year Founded
N/A

Profitability

Net Income
$-23,290,000.00
Pretax Margin
-46.96%

Debt

Sales & Book Value

Annual Sales
$48.34 million
Book Value
$0.48 per share

Miscellaneous

Free Float
35,514,000
Market Cap
$16.71 million
Optionable
Not Optionable
Beta
1.85

Social Links

10 Best Stocks to Own in 2025 Cover

Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:CEMI) was last updated on 2/1/2025 by MarketBeat.com Staff
From Our Partners